Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06833450
Recruiting Not applicable

Reliability of IUS in Crohn's Disease

NCT06833450 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Not applicable
Started
2022-01-19
Last updated
2025-02-18

Condition(s) studied

Crohn Disease (CD)

Investigational drug(s) / intervention(s)

Transabdominal intestinal ultrasound

Transabdominal intestinal ultrasound: Transabdominal intestinal ultrasound

Study summary

Transabdominal intestinal ultrasound (IUS) is gaining acceptance as a point-of-care test to objectively assess disease activity in Crohn's disease (CD).

In order to incorporate individual parameters in a future definition of transmural healing, and for the consistent application of IUS as a modality to assess treatment outcomes and establish therapeutic targets to ensure comparability between future studies, the inter-observer agreement should be determined for all relevant parameters.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Crohn's disease evolving for at least 1 months * Patient older than 18 years * Patient covered by French national health insurance * Written informed consent Exclusion Criteria: * Pregnant women or breastfeeding * Minor * Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)

Primary outcome measure(s)

  • Number of different IUS parameters between two operators — 1 year
    To assess in patients with CD the variability of IUS parameters between two operators

Trial sites (1)

FacilityCityRegionStatus
CHU d'Amiens Amiens France Recruiting

More Centre Hospitalier Universitaire, Amiens trials in France

Prevention of Chronic Postsurgical Pain in Chronic Opioid Users: Recruiting
Observance of Continuous Positive Pressure for the Treatment of Obstructive Sleep Apnea Syndrome Active, not recruiting
Effect of a Virtual Reality Program on Patient Comfort in the Surgical Intensive Care Unit Recruiting
Multimodal Quantified Analysis of Facial Movements: Comparison Between Pathological and Control Subjects Recruiting
Access to Kidney Transplant of Obese Patients Beginning Dialysis Recruiting

Other trials for the same condition

Kinetics of Transmural Healing in Patients With Crohns Disease Treated With Risankizumab (SKYRIZI®) Active, not recruiting
Tolerance of Local Administration of Cryopreserved Autologous Stromal Vascular Fraction Combined With Micrograft for the Treatment of Refractory Ano-perineal Fistulas in Crohn's Disease Recruiting
Concordance Between Inflammatory Activity Assessed by Enteric MRI With and Without Intestinal Distension Product in Patients With Ileal Crohn's Disease. Recruiting
Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study Recruiting
Evaluation of Therapeutic Strategy to Prevent Crohn's Disease Endoscopic poSToperatIve recurreNce Based on earlY Dosage of Faecal Calprotectin Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06833450 on ClinicalTrials.gov ↗ ← All trials in France